Navigation Links
Pairnomix Presents Systematic Approach To Identifying Approved Drugs That May Be Repurposed For Treatment Of Rare Genetic Diseases
Date:12/4/2016

HOUSTON, Dec. 3, 2016 /PRNewswire/ -- Pairnomix, LLC, a genetic research company and member of the Patient-Empowered Precision Medicine Alliance (PEPMA) recognized by the White House, today announced that findings from its first case study of an individualized approach to the identification of candidate therapies for a patient with epileptic encephalopathy caused by a mutation in the SCN8A gene were presented at the 70th Annual Meeting of the American Epilepsy Society in Houston, TX, December 2-6, 2016. 

Pairnomix' unique process involves creating a model of a patient's genetic mutation, learning about the functional consequences of that mutation, and testing approved drugs against the model to identify potential new treatment options.  Findings are provided to the patient's physician so together they can make better-informed healthcare decisions.

"We are very pleased to share these findings with the epilepsy community, and are gratified to be able to illustrate that it is possible to take a comprehensive approach to exploring opportunities for potentially repurposing approved drugs in the treatment of severe genetic epilepsies," said David Goldstein, PhD, Founding Scientist.

Pairnomix is working on additional cases and is proud of its ongoing collaboration with the KCNQ2 Cure Alliance to bring its highly personalized genetic evaluations to physicians for individuals living with KCNQ2 epileptic encephalopathy.

What is SCN8A?
SCN8A is a gene encoding the alpha-8 subunit of the Nav1.6 sodium channel. For more information, please reach out to the Cute Syndrome Foundation

About the Case Study
The individual was diagnosed with early infantile epileptic encephalopathy combined with global developmental delay and experienced lack of seizure control even after being prescribed many common anti-epileptic drugs (AEDs). The patient's physician ordered next-generation sequencing services, and a de novo mutation in the SCN8A gene was identified.

High throughput screening with more than 1,300 approved drugs identified 90 which significantly inhibited the gain-of-function phenotype conferred by the patient's mutation. These drugs may be potential therapeutic options for physicians to consider when evaluating patients with this specific mutation.  

About Pairnomix
Pairnomix™, a genetic research company, is committed to helping people living with rare diseases understand the genetic cause of their condition. Pairnomix' initial focus is to provide personalized research for people living with epilepsy and other disorders of the Central Nervous System. To learn more, please visit www.pairnomix.com.

Logo - http://photos.prnewswire.com/prnh/20151203/292940LOGO 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pairnomix-presents-systematic-approach-to-identifying-approved-drugs-that-may-be-repurposed-for-treatment-of-rare-genetic-diseases-300372255.html


'/>"/>
SOURCE Pairnomix, LLC
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
2. BioElectronics Presents FDA Reclassification Panel
3. Amgen Presents Positive Results From Talimogene Laherparepvec Phase 3 Study In Patients With Metastatic Melanoma
4. NewLink Genetics Presents Positive Phase 2 Data on Novel Immunotherapy, Tergenpumatucel-L, in Non-Small Cell Lung Cancer at the ASCO 2013 Annual Meeting
5. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
6. DelMar Pharmaceuticals Presents Additional Clinical Data from Ongoing Brain Cancer Study at ASCO
7. NewLink Genetics Presents Results from Two Phase 1 Studies with Immunotherapy Agent, Indoximod, at the ASCO 2013 Annual Meeting
8. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
9. Molly Fletcher to Speak at Astellas Presents Executive Womens Day at the FedEx St. Jude Classic
10. Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder
11. Discovery Labs Presents Final Assessment in a Series of Pharmacoeconomic Analyses that Explore Impact of Reintubation on Healthcare Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... --  Provista, a proven leader in the supply ... power, today announced a new resource area on Provistaco.com ... is the online home for case studies, articles on ... releases, slideshows and events. ... at their fingertips, viewers can also watch short videos ...
(Date:10/4/2017)... , Oct. 4, 2017 OBP ... self-contained, illuminating medical devices, today announced regulatory approval ... Surveillance Agency (or Agência Nacional de Vigilância Sanitária ... single-use, cordless surgical retractor with integrated LED light ... access, illumination and exposure of a tissue pocket ...
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the ... analysis system called the HORIZON at MIBio 2017 in ... subvisible and visible particulate matter in biopharmaceutical samples with unprecedented speed ... of the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
Breaking Medicine Technology:
(Date:10/13/2017)... TX (PRWEB) , ... October 13, 2017 , ... ... planning agency serving communities in the greater Dallas, Miami, and Raleigh regions, is ... boy fighting to overcome a rare and deadly chromosome abnormality. , After struggling ...
(Date:10/13/2017)... Pekin, IL (PRWEB) , ... October 13, 2017 ... ... Foundation, which established the certification process to promote standards of excellence for the ... iaedp™ Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at ...
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... ... 2017 , ... Talented host, actor Rob Lowe, is introducing ... new episode of "Success Files," which is an award-winning educational program broadcasted on ... subject in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
Breaking Medicine News(10 mins):